AMPH – Amphastar Pharmaceuticals Inc
AMPH — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
10.82
Margin Of Safety %
64
Put/Call OI Ratio
0.06
EPS Next Q Diff
0.62
EPS Last/This Y
0.87
EPS This/Next Y
0.41
Price
17.5
Target Price
25.17
Analyst Recom
2.71
Performance Q
-38.75
Upside
108.7%
Beta
0.94
Ticker: AMPH
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-13 | AMPH | 21.37 | 0.09 | 0.00 | 1215 |
| 2026-04-14 | AMPH | 21.36 | 0.09 | 0.09 | 1246 |
| 2026-04-15 | AMPH | 21.67 | 0.09 | 0.09 | 1246 |
| 2026-04-20 | AMPH | 22.95 | 0.04 | 0.00 | 1139 |
| 2026-04-23 | AMPH | 21.01 | 0.04 | 0.00 | 1199 |
| 2026-04-24 | AMPH | 21.43 | 0.04 | 0.00 | 1199 |
| 2026-04-27 | AMPH | 21.66 | 0.04 | 0.00 | 1200 |
| 2026-04-28 | AMPH | 21.84 | 0.04 | 0.00 | 1200 |
| 2026-04-29 | AMPH | 21.6 | 0.04 | 0.00 | 1200 |
| 2026-04-30 | AMPH | 21.96 | 0.04 | 0.00 | 1200 |
| 2026-05-01 | AMPH | 21.89 | 0.04 | 0.00 | 1202 |
| 2026-05-04 | AMPH | 22.73 | 0.04 | 0.00 | 1202 |
| 2026-05-05 | AMPH | 23.38 | 0.04 | 0.06 | 1225 |
| 2026-05-06 | AMPH | 23.91 | 0.04 | 0.00 | 1240 |
| 2026-05-07 | AMPH | 24.04 | 0.04 | 0.62 | 1240 |
| 2026-05-08 | AMPH | 18.99 | 0.05 | 0.55 | 1270 |
| 2026-05-11 | AMPH | 18.44 | 0.06 | 0.00 | 1294 |
| 2026-05-12 | AMPH | 17.5 | 0.06 | 3.00 | 1294 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-13 | AMPH | 21.36 | -2.3 | - | 3.27 |
| 2026-04-14 | AMPH | 21.36 | -2.3 | - | 3.27 |
| 2026-04-15 | AMPH | 21.67 | -2.3 | - | 3.27 |
| 2026-04-16 | AMPH | 21.80 | -2.3 | - | 3.27 |
| 2026-04-17 | AMPH | 22.84 | -2.3 | - | 3.27 |
| 2026-04-20 | AMPH | 22.94 | -2.3 | - | 3.27 |
| 2026-04-21 | AMPH | 21.22 | -2.3 | - | 3.27 |
| 2026-04-22 | AMPH | 20.99 | -2.3 | - | 3.27 |
| 2026-04-23 | AMPH | 21.01 | -2.3 | - | 3.27 |
| 2026-04-24 | AMPH | 21.45 | -4.7 | - | 3.25 |
| 2026-04-27 | AMPH | 21.68 | -4.7 | - | 3.25 |
| 2026-04-28 | AMPH | 21.85 | -4.7 | - | 3.25 |
| 2026-04-30 | AMPH | 21.95 | -4.7 | - | 3.25 |
| 2026-05-01 | AMPH | 21.89 | -4.7 | - | 3.25 |
| 2026-05-04 | AMPH | 22.73 | -4.7 | - | 3.25 |
| 2026-05-05 | AMPH | 23.38 | -4.7 | - | 3.25 |
| 2026-05-06 | AMPH | 23.91 | -4.7 | - | 3.25 |
| 2026-05-07 | AMPH | 24.00 | -4.7 | - | 3.25 |
| 2026-05-08 | AMPH | 18.99 | -4.7 | - | 3.25 |
| 2026-05-11 | AMPH | 18.45 | -4.7 | - | 3.25 |
| 2026-05-12 | AMPH | 17.50 | -4.7 | - | 2.97 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-13 | AMPH | -0.28 | 1.97 | 10.75 |
| 2026-04-14 | AMPH | -0.28 | 1.97 | 10.75 |
| 2026-04-15 | AMPH | -0.28 | 1.97 | 10.75 |
| 2026-04-16 | AMPH | -0.28 | 1.97 | 10.75 |
| 2026-04-17 | AMPH | -0.28 | 1.97 | 10.75 |
| 2026-04-20 | AMPH | -0.28 | 2.03 | 10.75 |
| 2026-04-21 | AMPH | -0.28 | 2.03 | 10.75 |
| 2026-04-22 | AMPH | -0.28 | 2.03 | 10.91 |
| 2026-04-23 | AMPH | -0.27 | 2.03 | 10.91 |
| 2026-04-24 | AMPH | -0.27 | 2.03 | 10.91 |
| 2026-04-27 | AMPH | -0.27 | 1.95 | 12.08 |
| 2026-04-28 | AMPH | -0.27 | 1.95 | 12.08 |
| 2026-04-29 | AMPH | -0.27 | 1.95 | 12.31 |
| 2026-04-30 | AMPH | -0.27 | 1.95 | 12.31 |
| 2026-05-01 | AMPH | -0.27 | 1.95 | 12.31 |
| 2026-05-04 | AMPH | -0.27 | 0.86 | 12.31 |
| 2026-05-05 | AMPH | -0.27 | 0.86 | 12.31 |
| 2026-05-06 | AMPH | -0.27 | 0.86 | 12.31 |
| 2026-05-07 | AMPH | -0.27 | 0.86 | 12.31 |
| 2026-05-08 | AMPH | -0.27 | 0.86 | 12.31 |
| 2026-05-11 | AMPH | -0.27 | 0.52 | 11.78 |
| 2026-05-12 | AMPH | -0.32 | 0.52 | 10.82 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.26
Avg. EPS Est. Current Quarter
0.68
Avg. EPS Est. Next Quarter
0.88
Insider Transactions
-0.32
Institutional Transactions
0.52
Beta
0.94
Average Sales Estimate Current Quarter
174
Average Sales Estimate Next Quarter
182
Fair Value
28.72
Quality Score
76
Growth Score
84
Sentiment Score
2
Actual DrawDown %
74.1
Max Drawdown 5-Year %
-72
Target Price
25.17
P/E
10.51
Forward P/E
5.31
PEG
2.55
P/S
1.07
P/B
1.01
P/Free Cash Flow
5.71
EPS
1.66
Average EPS Est. Cur. Y
2.97
EPS Next Y. (Est.)
3.37
Target Price Estimates Raised
Target Price Estimates Lowered
1
Profit Margin
11
Relative Volume
2.14
Return on Equity vs Sector %
-16.6
Return on Equity vs Industry %
2.1
EPS 1 7Days Diff
-0.3
EPS 1 30Days Diff
-0.35
EBIT Estimation
◆
AMPH
Healthcare
$17.50
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
30.7
Range 1M
2.3%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-11.2%
EPS NY
14.3%
52W%
2.8%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+189.8% upside
Upside
+189.8%
Quality
76
MoS
64%
Amphastar Pharmaceuticals, Inc.Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1976
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
AMPH
Latest News
—
Caricamento notizie per AMPH…
stock quote shares AMPH – Amphastar Pharmaceuticals Inc Stock Price stock today
news today AMPH – Amphastar Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch AMPH – Amphastar Pharmaceuticals Inc yahoo finance google finance
stock history AMPH – Amphastar Pharmaceuticals Inc invest stock market
stock prices AMPH premarket after hours
ticker AMPH fair value insiders trading